The rationale for using the bivalent ligand approach stems from the possibility of tackling the intricate array of AD, through dimeric structures capable of bridging independent recognition sites of validated targets (such as AChE, Aβ and BACE1). This evidence concerns the gene BACE1 and Alzheimer disease.